These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29345647)

  • 21. Improving MMR vaccination rates: herd immunity is a realistic goal.
    Cockman P; Dawson L; Mathur R; Hull S
    BMJ; 2011 Oct; 343():d5703. PubMed ID: 21971162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
    Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
    Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vaccination program against measles. 2 vaccinations closes the gap].
    Koczorek M
    MMW Fortschr Med; 2002 May; 144(19):12. PubMed ID: 12116545
    [No Abstract]   [Full Text] [Related]  

  • 26. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales.
    Sonnenberg P; Crowcroft NS; White JM; Ramsay ME
    Arch Dis Child; 2007 Sep; 92(9):786-9. PubMed ID: 17412744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surveillance and vaccination coverage of measles and rubella in Northern Italy.
    Amendola A; Bubba L; Piralla A; Binda S; Zanetti A; Pariani E; Ranghiero A; Premoli M; Pellegrinelli L; Coppola L; Gramegna M; Baldanti F; Zanetti A
    Hum Vaccin Immunother; 2015; 11(1):206-13. PubMed ID: 25483537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postlicensure epidemiology of childhood vaccination: the Danish experience.
    Hviid A
    Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia.
    Uno Y; Uchiyama T; Kurosawa M; Aleksic B; Ozaki N
    Vaccine; 2012 Jun; 30(28):4292-8. PubMed ID: 22521285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles transmission and vaccine effectiveness during a large outbreak on a densely populated island: implications for vaccination policy.
    Marin M; Nguyen HQ; Langidrik JR; Edwards R; Briand K; Papania MJ; Seward JF; LeBaron CW
    Clin Infect Dis; 2006 Feb; 42(3):315-9. PubMed ID: 16392073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vicar of vicarious vaccine-preventable diseases.
    Block SL
    Pediatr Ann; 2014 Jun; 43(6):214-9. PubMed ID: 24972415
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study.
    Glasser JW; Feng Z; Omer SB; Smith PJ; Rodewald LE
    Lancet Infect Dis; 2016 May; 16(5):599-605. PubMed ID: 26852723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Annual trends (2008-2011) in early childhood vaccination coverage for the French population: the Vaccinoscopie(®) study].
    Martinot A; Cohen R; Denis F; Gaudelus J; Lery T; Le Danvic M; Stahl JP
    Arch Pediatr; 2013 Aug; 20(8):837-44. PubMed ID: 23838068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial.
    Heijstek MW; Kamphuis S; Armbrust W; Swart J; Gorter S; de Vries LD; Smits GP; van Gageldonk PG; Berbers GA; Wulffraat NM
    JAMA; 2013 Jun; 309(23):2449-56. PubMed ID: 23780457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety concerns regarding combination vaccines: the experience in Japan.
    Andreae MC; Freed GL; Katz SL
    Vaccine; 2004 Sep; 22(29-30):3911-6. PubMed ID: 15364439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Public fear of vaccination: separating fact from fiction.
    Amanna I; Slifka MK
    Viral Immunol; 2005; 18(2):307-15. PubMed ID: 16035942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vaccine coverage in children].
    Gaudelus J
    Arch Pediatr; 2010 Jun; 17(6):955-7. PubMed ID: 20654978
    [No Abstract]   [Full Text] [Related]  

  • 39. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection.
    Díaz-Ortega JL; Bennett JV; Castañeda-Desales D; Quintanilla DM; Martínez D; de Castro JF
    Vaccine; 2014 Jun; 32(29):3680-6. PubMed ID: 24837512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Australian population cohort study of newly arrived refugee children: how effective is predeparture measles and rubella vaccination?
    Joshua PR; Smith MM; Koh AS; Woodland LA; Zwi K
    Pediatr Infect Dis J; 2013 Feb; 32(2):104-9. PubMed ID: 22955722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.